Maynard Um
-
-
-
-
-
-
-
Savara receives UK regulatory acceptance for rare lung disease drug
-
-
-
-
-
-
-
FDA files Savara's MOLBREEVI application for rare lung disease
-
-
-
-
-
-
-
Savara and PARI receive European patent for drug-device combination
-
-
-
-
-
-
-
Savara finds 50% more autoimmune PAP patients in US claims data study
-
-
-
-
-
-
-
H.C. Wainwright Downgrades Savara (SVRA) to Neutral
-
-
-
-
-
-
-
Savara (SVRA) Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution
-
-
-
-
-
-
-
Savara (SVRA) Initiates Rolling Submission of BLA to FDA for MOLBREEVI for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis
-
467,011 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


